DrugPatentWatch Database Preview
Drugs in Development Information for Prexasertib
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Prexasertib?
Prexasertib is an investigational drug.
There have been 14 clinical trials for Prexasertib.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Neoplasms, Head and Neck Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and St. Jude Children's Research Hospital.
There are three US patents protecting this investigational drug and sixty-four international patents.
Summary for Prexasertib
| US Patents | 3 |
| International Patents | 64 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2016-10-01) |
| Vendors | 30 |
Recent Clinical Trials for Prexasertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | Memorial Sloan Kettering Cancer Center | Phase 1/Phase 2 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | Eli Lilly and Company | Phase 1 |
| Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | St. Jude Children's Research Hospital | Phase 1 |
Clinical Trial Summary for Prexasertib
Top disease conditions for Prexasertib
Top clinical trial sponsors for Prexasertib
US Patents for Prexasertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Prexasertib | Start Trial | 5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate | Eli Lilly and Company (Indianapolis, IN) | Start Trial |
| Prexasertib | Start Trial | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA) | Start Trial |
| Prexasertib | Start Trial | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts | Eli Lilly and Company (Indianapolis, IN) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Prexasertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Prexasertib | Argentina | 106772 | 2035-12-07 | Start Trial |
| Prexasertib | Australia | 2016367041 | 2035-12-07 | Start Trial |
| Prexasertib | Brazil | 112018008398 | 2035-12-07 | Start Trial |
| Prexasertib | Canada | 3003914 | 2035-12-07 | Start Trial |
| Prexasertib | Chile | 2018001432 | 2035-12-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
